A 2-step strategy to reduce the need for methionine-loading tests to diagnose hyperhomocysteinemia

Journal of Laboratory and Clinical Medicine

Volumn 142, Issue 2, 2003, Pages 121-127

  Van De Laak, Marielle F ^b   Grobbee, Diederick E ^b   Van Der Griend, Rene ^b   De Valk, Harold W ^b   Algra, Ale ^b   Banga, Jan Dirk ^b   Van Der Graaf, Yolanda ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; METHIONINE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; REFERENCE VALUE; RISK FACTOR; VALIDATION PROCESS;

EID: 0141519187     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(03)00103-3     Document Type: Article

References (34)

1. Boers GH, Smals AG, Trijbels FJ, Fowler B, Bakkeren JA, Schoonderwaldt HC, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
2. Brattström L, Israelsson B, Norrving B, Bergqvist D, Thorne J, Hultberg B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.
3. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
4. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG, et al. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995;346:1395-8.
5. Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9.
6. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997;277:1775-81.
7. Verhoef P, Kok FJ, Kruyssen DA, Schouten EG, Witteman JC, Grobbee DE, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:989-95.
8. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-7.
9. Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman JC, et al. Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999;159:38-44.
10. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
11. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976;58:731-41.
12. Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 1993;34:2051-61.
13. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Inves 1986;77:1909-16.
14. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-14.
15. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7.
16. Clarke R, Collins R. Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998;5:249-55.
17. Willems HP, den Heijer M, Bus GM. Homocysteine and venous thrombosis: outline of a vitamin intervention trial. Semin Thromb Hemost 2000;26:297-304.
18. Vermeulen EG, Stehouwer CD, Twisk JW, van den Berg M, de Jong SC, Mackaay AJ, et al. Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial. Lancet 2000;355:517-22.
19. Mudd SH, Levy HL, Skovby F. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill; 1995:1279-1327.
20. Fowler B, Sardharwalla IB, Robins AJ. The detection of heterozygotes for homocystinuria by oral loading with L-methionine. Biochem J 1971;122:23P-24P.
21. Kluijtmans LA, van den Heuvel LP, Boers GH, Frosst P, Stevens EM, van Oust BA, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
22. de Jong SC, Stehouwer CD, van den Berg M, Kostense PJ, Alders D, Jakobs C, et al. Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease. Arterioscler Thromb Vasc Biol 1999;19:1316-24.
23. van der Griend R, Haas FJ, Duran M, Biesma DH, Meuwissen OJ, Banga JD. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998;132:67-72.
24. Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995;116:147-51.
25. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of arterial disease (SMART) study: rationale and design. Eur J Epidemiol 1999;15:773-81.
26. Donnelly JG, Pronovost C. Evaluation of the Abbott IMx fluorescence polarization immunoassay and the Bio-Rad enzyme immunoassay for homocysteine: comparison with high-performance liquid chromatography. Ann Clin Biochem 2000;37:194-98.
27. Yu HH, Joubran R, Asmi M, Law T, Spencer A, Jourma M, et al. Agreement among four homocysteine assays and results in patients with coronary atherosclerosis and controls. Clin Chem 2000;46:258-64.
28. Pfeiffer CM, Twite D, Shih J, Holets-McCormack SR, Gunter EW. Method comparison for total plasma homocysteine between the Abbott IMx analyzer and an HPLC assay with internal standardization. Clin Chem 1999;45:152-3.
29. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW, et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-5.
30. Moons KG, van Es GA, Deckers JW, Habbema JD, Grobbee DE. Limitations of sensitivity, specificity, likelihood ratio, and Bayes' theorem in assessing diagnostic probabilities: a clinical example. Epidemiology 1997;8:12-7.
31. Fermo I, Vigano 'D' Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.
32. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med 1989;114:473-501.
33. Silberberg J, Crook R, Fryer J, Wlodarczyk J, Nair B, Guo XW, et al. Gender differences and other determinants of the rise in plasma homocysteine after L-methionine loading. Atherosclerosis 1997;133:105-10.
34. van den Berg M, de Jong SC, Deville W, Rauwerda JA, Jakobs C, Pals G, et al. Variability of fasting and post-methionine plasma homocysteine levels in normo- and hyperhomocysteinaemic individuals. Neth J Med 1999;55:29-38.